Nanoparticle-Alginate Gels for Vascular X-Ray Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vascular imaging techniques face challenges with unstable contrast agents that dissociate or leach, leading to fuzzy imaging and misdiagnosis, particularly in areas near or within bone, where commercially available barium sulfate particles tend to clog capillaries and fail to enter the venous system.
Innovation Solution
A contrast agent comprising nanoparticles with a barium sulfate, barium carbonate, or calcium carbonate core capped with oligomers or polymers, dispersed in a gel precursor solution, which forms a stable gel upon crosslinking, allowing for effective imaging of the vasculature using X-ray techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If commercially available barium sulfate particles are used as contrast agent, then radiopacity is improved, but particle size causes capillary clogging and prevents venous system entry
Solution Approach 1:
The barium sulfate particles are segmented into nanoparticle sizes (1-100 nm) to enable capillary passage while maintaining radiopacity. This segmentation allows the contrast agent to enter the venous system without clogging capillaries, resolving the contradiction between radiopacity and particle size.
Solution Approach 2:
The patent creates composite materials by combining barium sulfate nanoparticles with biocompatible polymers (PEG, PVA, chitosan) to form core-shell structures. The polymer shell provides stability and prevents aggregation, allowing small radiopaque nanoparticle cores to function effectively without clogging while maintaining radiopacity.
2Ease of operation
If contrast agent is delivered in solution form, then ease of injection is improved, but instability causes dissociation and leaching leading to fuzzy imaging
Solution Approach 1:
The contrast agent is formulated as a composite material with radiopaque nanoparticle cores embedded in biocompatible polymer matrices (PEG, PVA, chitosan). This composite structure maintains stability in solution form, preventing dissociation and leaching while remaining injectable. The polymer matrix holds the nanoparticles together, ensuring stable contrast agent delivery.
Solution Approach 2:
The patent changes the physical and chemical parameters of the contrast agent by encapsulating nanoparticles in polymer shells with controlled molecular weights and crosslinking densities. This parameter optimization maintains solution stability and prevents aggregation during injection, resolving the contradiction between ease of injection and stability.
3Length of moving object
If nanoparticle size is reduced to avoid capillary clogging, then ability to enter venous system is improved, but radiopacity may be reduced
Solution Approach 1:
The patent creates core-shell composite structures where radiopaque nanoparticle cores (1-100 nm) are embedded in polymer shells. The core provides radiopacity while the shell provides stability and prevents aggregation. This composite approach maintains radiopacity even at nanoparticle sizes required for capillary passage.
Solution Approach 2:
The patent applies local quality by concentrating radiopaque material in the nanoparticle core while using biocompatible polymer shells for stability. This localized distribution of properties allows small particle size for capillary entry while maintaining radiopacity through the dense core material.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable and effective contrast agent that maintains radiopacity, allowing for clear X-ray imaging of fine vasculature without clogging issues, enhancing diagnostic accuracy and safety by using a minimally invasive delivery method.
Implementation Method 1
crosslinking the gel precursor solution to produce a gel, wherein the nanoparticle is dispersed in the gel
Implementation Method 2
Vascular imaging is a very important technique to distinguish the vascular network with similar or low X-ray attenuation. The contrast agent is critical for this technique.
Data Source
AI summary
Disclosed are capped nanoparticles that are effectively trapped within an aqueous gelling solution to produce stable gels and function as a contrast agent for vascular imaging. The contrast agent has good radioopacity, is inexpensive to produce, and is safe to handle. This provides a new method to image the fine vasculature of biological systems.